Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $173 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $173.
May 15, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Ascendis Pharma and maintained a price target of $173.
The reiteration of an Overweight rating and a high price target of $173 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100